Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Becoming Familiar with an Unknown dialect: My Language Learning Excursion - 2Two UN peacekeepers killed in explosion in Lebanon
- 3Canada cancels its 1st moon rover: 'It's hopefully not a lost cause'
- 4EU agrees on agriculture safeguards as fronts harden in Mercosur deal
- 5Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
- Journeys That could only be described as epic: Delightful Voyage Lines All over the Planet
- NASA to bring astronauts home from space station early due to a medical issue
- An Extended time of Self-Reflection: Self-awareness through Journaling
- Oil, energy and food: Which countries in Europe are most exposed to higher food prices?
- Tech Development Disclosed: A Survey of \Usefulness and Configuration in Concentration\ Tech Item
- Miss Thailand Pageant Contestant's Veneers Fall Out During Speech on Stage
- The Most recent Microsoft Surface Genius PC: Ideal for Very good quality Planning and Gaming Needs
- Netflix's Eddie Murphy documentary explains 'Saturday Night Live' beef: 'That's why I didn't go back for years'
- An Excursion Through Renowned Western Network programs
